Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Robert Scott Goodman, a director of Beyond Air, Inc. (XAIR), received a grant of stock options on 08/14/2025. The option grant is for 3,750 stock options with an exercise price of $2.45 per share and an expiration date of 08/14/2035. The option vests 25% on December 31, 2025, with the remainder vesting in equal annual installments on each December 31 for the next three years. After the grant, the reporting person beneficially owns 5,750 shares of common stock, which includes an additional 2,000 stock split-adjusted shares noted in the filing.
Beyond Air, Inc. filed a current report to note that it has issued a press release announcing its financial results for the first quarter ended June 30, 2025. The company stated that the press release, dated August 12, 2025, is attached as Exhibit 99.1 and is incorporated by reference into this report. The information in this report and the attached press release is being furnished rather than filed under securities laws, which affects how it is treated for certain liability and incorporation purposes.
Balyasny Asset Management and affiliated entities disclose beneficial ownership of 12,290,913 shares of Beyond Air common stock, representing approximately 9.99% of the outstanding class based on the issuer's reported share count. The reported position includes 8,956,504 shares issuable upon exercise of warrants, but a contractual 9.99% blocker prevents the Reporting Persons from exercising any warrants that would result in ownership above 9.99%.
The filing states each Reporting Person has sole voting and dispositive power over the 12,290,913 shares and identifies ADMF as the direct holder and an investment management client of BAM with rights to dividends and sale proceeds. Filers certify the securities were acquired in the ordinary course of business and not to influence control.
Beyond Air reported operational progress but faces a near-term funding gap. Revenue for the three months ended June 30, 2025 rose to $1.76 million from $0.68 million a year earlier, producing a $156,000 gross profit versus a prior gross loss. Operating losses narrowed to $7.62 million and net loss improved to $8.08 million from $13.06 million, reflecting lower R&D and SG&A spend. The company held $6.63 million of cash, marketable securities and restricted cash at period end but used $4.53 million in operating cash flow during the quarter. Management disclosed substantial doubt about meeting obligations with current resources and stated additional funding will be required within one year. Financing actions during the quarter included $2.4 million net ATM proceeds and a $2.0 million related-party advance; long-term debt outstanding under the Loan Agreement remains $11.5 million (facility terms include a 15% annual interest structure). The company has FDA PMA for LungFit PH and CE mark approval for additional indications, and effected a one-for-twenty reverse stock split with retroactive presentation of prior-period per-share amounts.
Beyond Air held a Special Meeting of stockholders on June 20, 2025, where shareholders approved a significant Reverse Stock Split proposal. Out of 86,369,869 outstanding shares, 48,476,717 shares were represented at the meeting, constituting a quorum.
Key details of the approved proposal:
- Authorizes the Board to implement a reverse stock split within one year
- Split ratio range between 1-for-10 and 1-for-50
- Voting results: 41,924,612 votes in favor, 6,382,862 against, 169,243 abstentions
This strategic move gives the Board flexibility to consolidate shares, potentially improving the company's market position and stock price structure. The strong shareholder support (86.5% of votes cast in favor) demonstrates confidence in the Board's management strategy.
Beyond Air (NASDAQ: XAIR) filed its Form 10-K Annual Report on June 29, 2025. The excerpt supplied consists almost entirely of XBRL taxonomy tags and entity identifiers, with no accompanying financial statements, narrative sections, risk factors, legal proceedings, or management discussion. Because the critical quantitative and qualitative disclosures normally included in a 10-K are absent from the provided content, no material information relevant to investors can be summarized from this excerpt.
Beyond Air (NASDAQ: XAIR) reported several significant developments in this 8-K filing:
Key Events:
- Released financial results for fiscal quarter and year ended March 31, 2025 (detailed results not provided in filing)
- Appointed Robert Goodman to Board of Directors on June 16, 2025 - Qualified as independent director under Nasdaq standards - Notable experience with BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, and Pfizer
- Submitted PMA supplement application to FDA for LungFit PH II, their next-generation therapeutic nitric oxide generator
The company filed two press releases as exhibits (99.1 and 99.2) detailing the financial results and FDA submission respectively. The appointment of Goodman strengthens the board with extensive healthcare industry expertise, while the FDA submission represents a significant regulatory milestone for their therapeutic device development program.